Chardan Capital initiated coverage of Gossamer Bio Inc (GOSS) at Buy on October 13, 2026.
Among three firms active over the past 90 days, three hold a bullish rating. As of October 30, 2026, eight analysts place the consensus mean at $97.31, the median at $96.90 and the range at $22.62 to $168.00.
Consensus Q4 FY2026 EPS is -$3.84, with revenue at $3.59 million. The next earnings report is on March 15, 2027.
